Screening for Chronic Kidney Disease in the Community Pharmacy. CRIERFAC Study: Description of the Methodology

Chronic kidney disease (CKD) is the existence of abnormalities in renal structure or function with an im-pact on health. This is usually considered when estimated glomerular filtration (eGF) falls under 60 mL/min/1.73m2. Its clinical course leads to renal replacement therapy (dialysis or transplant)...

Descripción completa

Detalles Bibliográficos
Autores: Ibáñez, LS, Guerrero, JE, Satué, E, León, NP, Asensio, MLMB
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repositorio:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:dnet:r-fisabio___::50349ce04b90f05566cecaa51405e02e
Acceso en línea:https://fisabio.portalinvestigacion.com/publicaciones/21006
Access Level:acceso abierto
Palabra clave:Chronic kidney disease
Community pharmacy
Screening
Descripción
Sumario:Chronic kidney disease (CKD) is the existence of abnormalities in renal structure or function with an im-pact on health. This is usually considered when estimated glomerular filtration (eGF) falls under 60 mL/min/1.73m2. Its clinical course leads to renal replacement therapy (dialysis or transplant) when eGF falls under 15 mL/min/1.73m2. Screening in at risk populations has been proven to be cost-effective. The aim of this work is to perform CKD screening in the community pharmacy. In this publication we report and justify the methodology in detail. Methodology: Pharmacists from the community pharmacies taking part selected patients who com-plied with inclusion and not exclusion criteria. Creatinine was measured by means of a finger prick and eGF calculated with the formula CKD-EPI. If this is lower than a set value, which depends on age, referral to the general practitioner takes place. Results: a total of 141 out of 200 pharmacies took part in the study. In all 2116 patients were recruited and 116 patients were lost. The final sample size was 2000 patients. Discussion: the protocol was successfully implemented by community pharmacists and was ex-tremely well received by community pharmacy users. The age adjustment for eGF thresholds provides a novel additional filter. The aim is not to overburden primary care centres with potential referrals of false positives. Confirmation of the diagnosis is subject to voluntary communication by the patient to the pharmacist